Paul, exactly, for anyone without the pain of massive capital loss so far, it is probably the best buy of all biotech on ASX bar none.
With regards to strategy,I think from the announcement today , it is safe to say that there is a very definite management strategy, they have place the house of TAVR and SVAR. For them it is full steam ahead , damn the torpedoes.
Ann: Promising Interim Results from TAVR Animal Study, page-27
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.91 | 475 | 2 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |